ARTICLE | Clinical News
Iressa gefitinib regulatory update
October 6, 2014 7:00 AM UTC
EMA's CHMP recommended approval of a Type II variation application for Iressa gefitinib from AstraZeneca for first-line treatment of advanced or metastatic, EGFR mutation-positive non-small cell lung...